Our Reports
Automotive Reports Electronics & Semiconductor Telecom & IT Technology & IT Consumer Goods Healthcare Food & Beverages Chemical
Our Links
About Us Contact Us Press Release News Our Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com


The Testosterone Replacement Therapy Market is Predict to reach USD 2.5 billion by 2031, at a CAGR of 4.1%

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Testosterone Replacement Therapy Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Testosterone Replacement Therapy Market size is expected to reach $2.5 billion by 2031, rising at a market growth of 4.1% CAGR during the forecast period.

Selective androgen receptor modulators (SARMs) are a class of compounds that selectively target androgen receptors in specific tissues, such as muscle and bone, while minimizing the androgenic effects in other tissues. SARMs hold promise as alternative treatments for hypogonadism, offering potential benefits in terms of muscle building, bone health, and sexual function, with fewer androgenic side effects compared to traditional testosterone replacement therapies.

Testosterone Replacement Therapy Market Size - By Region

The Hospital segment is anticipated to have a CAGR of 4.8% during (2024 - 2031). Hospitals serve as centers for specialized medical care, including the diagnosis and treatment of hormone-related disorders such as hypogonadism. Patients with severe or complex cases of hypogonadism may be referred to hospital endocrinology departments or specialized clinics within hospitals for comprehensive evaluation and management, including TRT initiation and monitoring.

The Injectables segment is leading the Global Testosterone Replacement Therapy Market by Product Type in 2023 thereby, achieving a market value of $1.7 billion by 2031. Injectable testosterone formulations offer high efficacy and consistent testosterone delivery. Once administered, injectables provide a sustained release of testosterone into the bloodstream, maintaining stable hormone levels over an extended period. This consistent delivery ensures optimal therapeutic effects, including improvements in libido, erectile function, muscle mass, bone density, and overall well-being, making injectables a preferred choice for many patients and healthcare providers.

The Testosterone Undecanoate segment is poised to have a CAGR of 3.7% during (2024 - 2031). The less frequent dosing schedule of testosterone undecanoate enhances patient convenience and reduces the burden of treatment. Patients may appreciate the convenience of fewer clinic visits and injections, leading to improved treatment adherence and patient satisfaction. Also, testosterone undecanoate provides stable and consistent testosterone levels over the dosing interval, minimizing fluctuations and ensuring hormonal balance.

Full Report: https://www.kbvresearch.com/testosterone-replacement-therapy-market/

The North America region dominated the Global Testosterone Replacement Therapy Market by Region in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $1 billion by 2031. The Europe region is exhibiting a CAGR of 3.7% during (2024 - 2031). Additionally, The Asia Pacific region would experience a CAGR of 5% during (2024 - 2031).

List of Key Companies Profiled

  • Endo International PLC
  • AbbVie, Inc.
  • Pfizer, Inc.
  • Eli Lilly And Company
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Ferring Holdings SA
  • Marius Pharmaceuticals LLC
  • Besins Healthcare Monaco S.A.M.
  • Acrux Limited

Testosterone Replacement Therapy Market Report Segmentation

By End User

  • Clinics
  • Hospital

By Product Type

  • Injectables
  • Topical
  • Others

By Active ingredient

  • Testosterone Cypionate
  • Testosterone Undecanoate
  • Testosterone Enanthate
  • Testosterone
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Australia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Related Reports:



SUBSCRIPTION MODEL